Jeevan Scientific Technology Ltd
Jeevan Scientific Technology Limited established in 1999, is a clinical research organization with a focus on Pharmacovigilance (PV- tracking and reporting adverse drug reactions after drug launch) & clinical trial business (CT). Its target market is small and medium-sized pharma companies for PV & for CT it focuses on both domestic & international markets. [1]
- Market Cap ₹ 78.7 Cr.
- Current Price ₹ 50.8
- High / Low ₹ 70.0 / 42.2
- Stock P/E 127
- Book Value ₹ 32.9
- Dividend Yield 0.00 %
- ROCE -0.86 %
- ROE -2.16 %
- Face Value ₹ 10.0
Pros
Cons
- The company has delivered a poor sales growth of 8.65% over past five years.
- Promoter holding is low: 38.7%
- Company has a low return on equity of 3.90% over last 3 years.
- Debtor days have increased from 93.4 to 113 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1.26 | 6.37 | 13.45 | 17.34 | 17.46 | 19.25 | 25.43 | 20.57 | 40.42 | 56.55 | 36.18 | 38.50 | 42.87 | |
2.66 | 5.31 | 11.10 | 15.15 | 14.24 | 15.93 | 19.62 | 26.35 | 23.79 | 39.46 | 34.83 | 34.12 | 35.88 | |
Operating Profit | -1.40 | 1.06 | 2.35 | 2.19 | 3.22 | 3.32 | 5.81 | -5.78 | 16.63 | 17.09 | 1.35 | 4.38 | 6.99 |
OPM % | -111.11% | 16.64% | 17.47% | 12.63% | 18.44% | 17.25% | 22.85% | -28.10% | 41.14% | 30.22% | 3.73% | 11.38% | 16.31% |
0.03 | 0.10 | 0.10 | 0.40 | 0.57 | 0.90 | 0.97 | 2.49 | 2.38 | 5.90 | 1.06 | 0.69 | 0.40 | |
Interest | 0.58 | 0.66 | 0.74 | 1.28 | 1.48 | 1.67 | 2.09 | 2.57 | 1.88 | 0.96 | 1.01 | 0.75 | 0.71 |
Depreciation | 0.27 | 0.27 | 0.28 | 0.67 | 1.18 | 2.06 | 3.07 | 3.91 | 3.96 | 3.68 | 5.02 | 5.55 | 5.29 |
Profit before tax | -2.22 | 0.23 | 1.43 | 0.64 | 1.13 | 0.49 | 1.62 | -9.77 | 13.17 | 18.35 | -3.62 | -1.23 | 1.39 |
Tax % | 0.00% | 0.00% | 0.00% | 34.38% | 8.85% | 46.94% | 16.05% | -20.06% | 14.58% | 33.19% | -16.85% | -14.63% | |
-2.21 | 0.23 | 1.44 | 0.42 | 1.03 | 0.25 | 1.36 | -7.81 | 11.26 | 12.26 | -3.00 | -1.05 | 0.62 | |
EPS in Rs | -3.66 | 0.38 | 2.38 | 0.70 | 1.11 | 0.22 | 0.89 | -5.10 | 7.36 | 8.01 | -1.94 | -0.68 | 0.40 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6.79% | 14.98% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 20% |
5 Years: | 9% |
3 Years: | -2% |
TTM: | 18% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 129% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 23% |
3 Years: | -21% |
1 Year: | -10% |
Return on Equity | |
---|---|
10 Years: | 5% |
5 Years: | 4% |
3 Years: | 4% |
Last Year: | -2% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6.04 | 6.04 | 6.04 | 6.04 | 9.28 | 11.46 | 15.30 | 15.30 | 15.30 | 15.30 | 15.48 | 15.48 | 15.48 |
Reserves | -3.93 | -3.70 | -2.26 | -1.85 | 8.15 | 8.11 | 17.47 | 9.63 | 20.95 | 35.28 | 32.84 | 33.32 | 35.42 |
4.63 | 4.34 | 6.42 | 11.08 | 8.45 | 18.78 | 18.15 | 17.95 | 10.34 | 12.55 | 8.84 | 5.80 | 8.67 | |
1.01 | 1.20 | 6.75 | 5.30 | 5.10 | 10.95 | 9.90 | 10.00 | 17.18 | 14.75 | 6.59 | 5.32 | 6.21 | |
Total Liabilities | 7.75 | 7.88 | 16.95 | 20.57 | 30.98 | 49.30 | 60.82 | 52.88 | 63.77 | 77.88 | 63.75 | 59.92 | 65.78 |
1.68 | 1.44 | 1.16 | 8.60 | 13.83 | 23.79 | 26.61 | 23.69 | 20.53 | 19.07 | 24.03 | 20.20 | 24.29 | |
CWIP | 0.00 | 0.00 | 4.59 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.53 | 0.53 | 1.03 | 1.03 | 1.03 | 1.03 | 0.00 | 2.00 | 2.00 | 2.00 |
6.07 | 6.44 | 11.20 | 11.44 | 16.62 | 24.48 | 33.18 | 28.16 | 42.21 | 58.81 | 37.72 | 37.72 | 39.49 | |
Total Assets | 7.75 | 7.88 | 16.95 | 20.57 | 30.98 | 49.30 | 60.82 | 52.88 | 63.77 | 77.88 | 63.75 | 59.92 | 65.78 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.69 | 0.27 | 2.39 | 3.95 | -8.13 | 3.73 | 2.41 | -1.19 | 4.73 | 19.56 | -6.29 | 2.74 | |
-0.05 | -0.02 | -4.59 | -4.07 | -6.41 | -12.43 | -6.20 | -1.02 | -0.80 | -1.20 | -7.27 | -4.69 | |
0.74 | -0.22 | 2.21 | 0.23 | 14.57 | 9.88 | 6.07 | 0.44 | -0.13 | 5.67 | -10.03 | -3.66 | |
Net Cash Flow | 0.00 | 0.03 | 0.01 | 0.11 | 0.03 | 1.18 | 2.28 | -1.77 | 3.80 | 24.03 | -23.59 | -5.61 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 1,118.17 | 143.82 | 199.19 | 152.19 | 232.25 | 305.65 | 208.26 | 106.47 | 112.52 | 49.12 | 117.83 | 113.10 |
Inventory Days | 72.11 | 105.50 | 100.18 | |||||||||
Days Payable | 98.78 | 318.92 | 184.48 | |||||||||
Cash Conversion Cycle | 1,118.17 | 143.82 | 199.19 | 152.19 | 232.25 | 305.65 | 208.26 | 106.47 | 112.52 | 22.45 | -95.59 | 28.80 |
Working Capital Days | 834.29 | 230.92 | 92.27 | 103.99 | 149.26 | 181.46 | 117.27 | 42.23 | 76.03 | 65.90 | 156.77 | 178.52 |
ROCE % | 13.26% | 25.71% | 15.08% | 12.69% | 6.73% | 8.31% | -15.29% | 33.64% | 27.85% | -4.34% | -0.86% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Nov - Copy of Newspaper Cuttings of the Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30th September, 2024.
-
Announcement under Regulation 30 (LODR)-Change in Management
8 Nov - Approval of financial results and key management changes.
- Un Audited Financial Results ( Standalone And Consolidated) For The Quarter And Half Year Ended 30.09.2024 8 Nov
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 08.11.2024
8 Nov - Approval of financial results and key management changes.
-
Board Meeting Intimation for The Meeting To Be Held On 08.11.2024
2 Nov - Board meeting scheduled for November 8, 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Contract Research Organisation[1]
The company forayed into the Clinical research space in 2014 with the aim of providing quality and cost-effective services to Pharma and biotech companies across the globe and now primarily focuses on specialty drugs like biosimilars and is building expertise on the same.